Pfizer fights approval of generic Ibrance

Pfizer is seeking to block a generic version of its cancer drug Ibrance (palbociclib) from entering the market until the patent covering the drug expires in May 2036.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pfizer sued over COVID-19 antiviral drug

28 June 2022 Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.

Big Pharma

Pfizer sues India generic drugmaker over cancer drug

14 January 2021 Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

Generics

Delhi court approves Natco generic of Novartis cancer drug

29 August 2019 The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Pfizer fights approval of generic Ibrance

More on this story

Editor's picks

Editor's picks

More features